more vaccinated lowrisk people wont benefit from covid19 pill paxlovid pfizer study suggests rebound cases are real and seriously underestimated less understood about paxlovid and covid in general is a persons chance of rebound a phenomenon in which a person recovers from an infection and tests negative only to redevelop covid symptoms or test positive within eight days after recovering in a statement at the time pfizer ceo albert bourla said with up to 4050 of people around the world estimated to be high risk we believe there remains a significant unmet need for treatment options to help combat this disease and we will continue to prioritize efforts to advance the development of paxlovid and with paxlovid studies have found it significantly reduced chance of hospitalization and death diaz added we did not see an association between viral rebound and severe disease or resistance the company wrote six months ago dr joseph boselli said he was prescribing the antiviral drug paxlovid to nearly everyone who turned up at his practice with covid more in a statement pfizer cited data from its 2021 clinical trials that found the risk of viral rebound after taking the drug to be uncommon and not uniquely associated with any specific treatment while researchers found the drug reduced hospitalization by roughly 75 when given soon after infection to people 65plus it saw no measurable benefit for people ages 40 to 64 more what to know about paxlovid the covid19 therapy that biden is taking in june pfizer announced it would stop enrolling standardrisk patients in a trial to see if the broader public might benefit president joe biden and his wife jill bidens top medical adviser dr anthony fauci and dr rochelle walensky the head of the centers for disease control and prevention each experienced rebound youri benadjaoud with abc news medical unit contributed to this report pfizers paxlovid joe raedlegetty images file more theres a good chance that youll have a rebound whether you take treatment or not he said the tincture of time has showed us that while it is a great drug and it really does work its not meant for everybody said boselli fauci says hes taking 2nd course of paxlovid after experiencing rebound with the antiviral treatment also one study released this summer found little to no benefit for younger adults when looking at some 100000 patients in israel the drug does make a real and measurable difference in the trajectory of the infection she said us officials more worried about covid deaths than reports of mild rebound health experts and us regulators says they are more concerned that vulnerable patients arent getting the drug than they are concerned about healthy people rebounding i got four calls today but i only gave paxlovid to two because they were older said boselli an internal medicine physician at jefferson health in philadelphia dr robert califf awaits the start of a hearing before the senate health education labor and pensions committee